Optimistic Long-Term Outlook for ACADIA Pharmaceuticals' Daybue Drives Buy Rating
BMO Capital Initiates Coverage On ACADIA Pharmaceuticals With Outperform Rating, Announces Price Target of $31
ACADIA Pharmaceuticals Analyst Ratings
RBC Capital Reiterates Outperform on ACADIA Pharmaceuticals, Maintains $29 Price Target
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)
Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Integer Holdings (ITGR) and ACADIA Pharmaceuticals (ACAD)
B of A Securities: Maintaining the ACADIA Pharmaceuticals (ACAD.US) rating, adjusted from neutral to neutral, and adjusted the target price from $26.00 to $22.00.
B of A Securities Maintains Neutral on ACADIA Pharmaceuticals, Lowers Price Target to $22
Neutral Outlook on ACADIA Pharmaceuticals Amidst Revenue Miss and Revised Penetration Forecasts
Buy Rating for ACADIA Pharmaceuticals Based on Promising Drug Prospects and Financial Stability
HC Wainwright & Co. : The ACADIA Pharmaceuticals (ACAD.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $33.00 to $27.00.
ACADIA Pharmaceuticals Analyst Ratings
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $30
Stifel Adjusts Price Target on ACADIA Pharmaceuticals to $21 From $26, Keeps Hold Rating
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Beam Therapeutics (BEAM) and Mirum Pharmaceuticals (MIRM)
Mizuho Bank: Maintains ACADIA Pharmaceuticals (ACAD.US) rating, adjusted from neutral to neutral, and adjusted the target price from $25.00 to $21.00.
Maintaining Buy Rating on ACADIA Pharmaceuticals Amidst Daybue's Long-Term Growth Prospects
RBC Capital Remains a Buy on ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals Analyst Ratings